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Lackey DE, Burk DH, Ali MR, Mostaedi R, Smith WH, Park J,
Scherer PE, Seay SA, McCoin CS, Bonaldo P, Adams SH. Con-
tributions of adipose tissue architectural and tensile properties toward
defining healthy and unhealthy obesity. Am J Physiol Endocrinol
Metab 306: E233–E246, 2014. First published December 3, 2013;
doi:10.1152/ajpendo.00476.2013.—The extracellular matrix (ECM)
plays an important role in the maintenance of white adipose tissue
(WAT) architecture and function, and proper ECM remodeling is
critical to support WAT malleability to accomodate changes in energy
storage needs. Obesity and adipocyte hypertrophy place a strain on the
ECM remodeling machinery, which may promote disordered ECM
and altered tissue integrity and could promote proinflammatory and
cell stress signals. To explore these questions, new methods were
developed to quantify omental and subcutaneous WAT tensile
strength and WAT collagen content by three-dimensional confocal
imaging, using collagen VI knockout mice as a methods validation
tool. These methods, combined with comprehensive measurement of
WAT ECM proteolytic enzymes, transcript, and blood analyte anal-
yses, were used to identify unique pathophenotypes of metabolic
syndrome and type 2 diabetes mellitus in obese women, using mul-
tivariate statistical modeling and univariate comparisons with weight-
matched healthy obese individuals. In addition to the expected differ-
ences in inflammation and glycemic control, approximately 20 ECM-
related factors, including omental tensile strength, collagen, and
enzyme transcripts, helped discriminate metabolically compromised
obesity. This is consistent with the hypothesis that WAT ECM
physiology is intimately linked to metabolic health in obese humans,
and the studies provide new tools to explore this relationship.
matrix metalloproteinase; bariatric surgery; adipose inflammation;
type 2 diabetes mellitus; extracellular matrix
WHITE ADIPOSE TISSUE (WAT) is the primary site of energy
storage in humans and by its nature must be malleable to
respond to changes in energy balance through expansion and
contraction. Under healthy conditions, changes in WAT archi-
tecture and the extracellular matrix (ECM) are coordinated
with alterations in adipocyte size to accommodate fat storage
needs. In contrast, sustained excessive energy intake with
concomitant development of hypertrophic adipocytes creates a
strain on ECM adaptation with pathophysiological conse-
quences such as inflammation and insulin resistance.
Adipose transcript abundances of several ECM-related
genes were increased in obese compared with nonobese human
subjects, including cell adhesion molecules and ECM receptor
interaction genes, whereas weight loss after gastric bypass
surgery led to decreased expression of these genes (18). Col-
lagen VI is enriched in adipose tissue, and visceral WAT mass
is related to increased expression of collagen 63 in humans
and in genetically obese mice (21, 38). Some studies have
indicated that, at least in severe obesity, WAT fibrosis is more
prevalent compared with nonobese individuals and that fibrosis
decreases with weight loss (13, 14), and this is believed to play
a role in obesity-associated inflammation. Genetically obese
ob/ob mice deficient in collagen VI (and thus lower fibrosis)
fed a high-fat diet have improved glucose tolerance, insulin
signaling, and triglyceride disposal with greater adipocyte size
along with reduced WAT inflammation (21). Further highlight-
ing the associations between ECM and metabolic phenotypes,
studies have shown changes in insulin sensitivity, adipocyte
size, and visceral adipose depot mass with genetic or chemical
modulation of the ECM proteolytic and fibrinolytic systems in
mice (7, 11, 12, 28, 30, 56). In humans, obese subjects with
metabolic syndrome have greater serum levels of plasminogen
activator inhibitor-1 (PAI-1) and matrix metalloproteinase-9
(MMP-9), factors that are involved in ECM remodeling (3, 23).
Thus, evidence clearly points to an important role for the ECM
and its modulators in driving and/or reflecting WAT-specific
and system-wide metabolic and inflammatory outcomes.
Interestingly, a subset of obese women are considered met-
abolically healthy (58), but the specific phenomena that under-
lie or track health vs. disease manifestations in obesity remain to
be identified. It is reasonable to consider that differences in the
WAT ECM, fibrosis, and inflammation play a role in this regard.
Understanding the specific factors that underlie changes in WAT
structure and ECM in response to changes in nutritional status and
obesity will provide insight into the events that lead to or accom-
pany metabolic disease. It has been difficult to unravel natural
nonpathological events that accompany weight gain from those
that lead to metabolic dysfunction. A case in point is the
observation that severe diet-induced obesity (DIO) in mice is
accompanied by inflammation and areas in WAT of adipocyte
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death, in synchrony with reduced insulin sensitivity (35, 46,
59). Similar increases in macrophage infiltration and inflam-
mation also occur in humans (3, 23). This suggests that
macrophages have a functional role in “repair” of dysfunc-
tional “injured” WAT and that chronic inflammation stemming
from macrophage activation contributes to insulin resistance.
However, we and others have shown that WAT macrophage
infiltration markers are strongly correlated with body weight
over a large range in nonobese and moderately obese DIO mice
(52, 53), supporting a normal physiological role for macro-
phages in the course of well-controlled WAT expansion and
remodeling. DIO mouse WAT is enriched in macrophages with
a combination of classic M1 and alternative M2 characteristics,
and genes involved in remodeling and angiogenesis are up-
regulated (42). Altogether, these observations highlight that the
nature of the WAT, and not its bulk per se, may be the driver
of metabolic disease susceptibility in obesity.
Considering the uncertainties surrounding the roles of the
ECM and its potential regulators on metabolic health or obe-
sity-associated disease, we tested the hypothesis that the ECM
and WAT architecture phenotype differs in metabolically
healthy and unhealthy WAT in equally obese women. Specif-
ically, we tested the relationships between indices of metabolic
dysfunction, inflammation, and subcutaneous (sc) and visceral
(omental) WAT structure by integrating novel biophysical
parameters, tissue proteolytic activity, patterns in a suite of
WAT inflammation- and ECM-related gene transcripts, and
unique three-dimensional collagen content analyses to identify
multivariate signatures that mark health and disease. Since
some treatments used for metabolic disorders [e.g., thiazoli-
dinediones (TZD) and statins] have been shown to influence
ECM integrity and remodeling (9, 17, 26, 39), our primary aim
was to compare the ECM phenotype in weight-matched
healthy vs. unhealthy [metabolic syndrome (MetS)] obese
women not taking these classes of medications. In addition, we
had an opportunity to make a secondary comparison between
weight-matched type 2 diabetic (T2DM) women and healthy
obese women to understand whether diabetes also impacts the
WAT ECM phenotype.
METHODS
Collagen 6a1 knockout mice. Male Col6a1/ [Col6 knockout
(KO)] mice and wild-type (WT) control littermates were obtained
from the laboratory of Bonaldo et al. (4). Eighteen- to 25-wk-old male
mice were maintained in the University of California Davis vivarium
on rodent chow (Picolab Mouse Diet 20; Purina LabDiet). Mice were
briefly food deprived (between 3 and 8 h starting at 0600) prior to
being deeply anesthetized via isoflurane inhalation (3% in O2). Ret-
roperitoneal (RP) fat pads, epididymal (EPI) fat pads, femoral sc fat
pads, and liver were excised and weighed. The right RP fat pad was
put into ice-cold Hanks’ balanced salt solution (HBSS) before tensile
strength was measured (described below). Extreme care was exercised
in dissection to ensure that the integrity of the depot sheath was not
compromised, since this could impact tensile strength measurements.
In addition, one fat pad each for EPI and sc WAT was fixed in 10%
neutral buffered formalin and paraffin embedded. The animal protocol
was approved by the University of California Davis Institutional
Animal Care and Use Committee according to Animal Welfare Act
guidelines.
Healthy and metabolically compromised obese human subjects. All
human protocols were approved by the University of California at
Davis Institutional Review Board, and all participants provided writ-
ten informed consent. Subjects between 20 and 55 yr of age and BMI
between 35 and 55 undergoing bariatric surgery at the University of
California Davis Medical Center were recruited. Adult women with
fasting glucose 100 mg/dl, total insulin 19 U/ml, triglycerides
150 mg/dl, HDL 39 mg/dl, systolic blood pressure 140 mmHg,
and diastolic blood pressure 90 mmHg and who were not taking
medication for T2DM or dyslipidemia were considered metabolically
healthy and free of metabolic syndrome (n  12). Nondiabetic
subjects with fasting glucose 100 mg/dl or total insulin 19 U/ml
as well as dyslipidemia (triglyceride 150 mg/dl or HDL 39 mg/dl)
or hypertension (systolic blood pressure 140 mmHg or diastolic
blood pressure 90 mmHg) who were not previously taking medica-
tion for blood sugar control or dyslipidemia were assigned to the MetS
group (n  10). Prior to surgery, subjects underwent a 2-day clear
liquid diet and bowel preparation with GoLYTELY (polyethylene
glycol-electrolyte solution; Braintree Laboratories, Braintree, MA),
followed by 1 g of neomycin treatment. Omental and sc WAT samples
were collected during bariatric surgery under Diprivan (propofol) and
sevoflurane anesthesia. Tissue samples were subsectioned for fixation
in 10% neutral buffered formalin, stored in ice-cold HBSS for mea-
suring tensile strength, or flash-frozen and stored at 80°C. The
primary comparison for this study was healthy vs. MetS subjects;
however, samples were also opportunistically collected from obese
women previously diagnosed with T2DM (n  10), for which sec-
ondary comparisons with healthy obese were conducted. For this
subject cohort, fasting blood sugar was 126 mg/dl, and subjects had
varying numbers of additional MetS components either pharmacologi-
cally treated and managed or untreated. Medications used for glucose
management included metformin and insulin glargine; no subject was
taking any medications in the TZD class. For dyslipidemia management,
some T2DM subjects were using simvastatin, lovastatin, ezetimibe, and
niacin. For hypertension management, some T2DM group members were
using one or more of atenolol, diltiazem, hydrochlorothiazide, lisinopril,
furosemide, carvedilol, losartan, metoprolol, olmesartan, or valsartan.
Tensile strength. Tensile strength was measured in fresh tissue.
Tensile strength of RP WAT from WT and collagen 6a1 KO mice and
sc WAT and omental WAT from human subjects was measured using
a DMT560 tissue puller (Danish MyoTechnology) fitted with custom
tissue clamps (Fig. 1). For mouse RP WAT, one whole fat pad per
mouse, carefully dissected so as to maintain the integrity of the outer
sheath of the pad, was mounted on the clamps, cranial end to the top
clamp and caudal end to the bottom clamp. Dimensions of the fat pad
were recorded for use in calculating tensile strength. For human WAT
samples, an 2-cm-long surgical biopsy was clamped to the tissue
puller. The tissue was pulled until complete rupture at 50 m/s, and
force and displacement were measured during the pulling. Peak force
was the greatest force attained during pulling. Tensile strength is
defined as peak force/tissue cross-sectional area.
Gelatin zymography. Flash-frozen RP WAT samples (mice) or sc
and omental WAT (humans) were homogenized in zymography
protein lysis buffer (10 mM sodium phosphate buffer, pH 7.2, 150
mM sodium chloride, 1% Triton X-100, 0.1% SDS, 0.5% sodium
deoxycholate, and 0.2% sodium azide) and 100 mg of tissue/200 l of
buffer. Lysates were centrifuged at 10,000 g for 10 min to clear.
Protein concentrations were quantified using the bicinchoninic protein
assay (Thermo Fisher Scientific). Thirty micrograms of protein from
each sample was loaded onto Novex 10% Zymogram Gelatin poly-
acrylamide gels in Novex Tris-Glycine SDS Sample Buffer (Life
Technologies). Gels were electrophoresed in Tris-Glycine SDS buf-
fer, renatured in renaturing buffer (Life Technologies), incubated in
developing buffer (Life Technologies) at 37°C overnight, and stained.
Gels were dried and scanned (GS-800 Calibrated Densitometer; Bio-
Rad, Hercules, CA), and bands of clearance were analyzed by densi-
tometry (Quantity One version 4.6.9; Bio-Rad).
Fluorogenic proteolytic activity assay. Twenty micrograms of
protein from flash-frozen WAT homogenized with zymography pro-
tein lysis buffer was assayed for proteolytic activity in 1	 assay
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buffer (50 mM HEPES, 10 mM CaCl2, 0.05% Brij-35, pH 7.0)
containing 5 M OmniMMP fluorogenic substrate (stock 15 mM in
DMSO; Enzo Life Sciences) and incubated in black 96-well plates for
24 h in the dark at room temperature. MMP proteolytic activity was
measured using excitation wavelength at 320 nm and emission wave-
length at 405 nm on a Molecular Devices Spectra Gemini instrument.
Histology. WAT was fixed in 10% neutral buffered formalin then
embedded in paraffin, sectioned at 6-m thickness onto slides, and
stained with Picrosirius red for collagen identification. Slides were
imaged at 	20 magnification. Collagen staining and cross-sectional
adipocyte area were quantified using National Institutes of Health
(NIH) Image J software (version 1.46r) from 10 fields for collagen
analysis and from 200 cells in five fields for adipocyte area mea-
surement. Analysis was conducted in a blinded fashion.
Confocal microscopy for three-dimensional collagen imaging and
quantitation. RP WAT from WT and Col6a1 KO mice or sc WAT and
omental WAT from human subjects were cut to 3 	 3 	 3 mm and fixed
in 10% neutral buffered formalin, washed in PBS for 1 h, and perme-
abilized with 0.3% Triton X-100 in PBS for 10 min followed by 0.4 U
proteinase K (Sigma) in 10 mM Tris·HCl, pH 7.4, for 5 min and then
100% methanol for 30 min. Samples were washed with 0.1% Triton
X-100 in PBS 3 	 20 min, stained overnight at 4°C with 200 mg/ml
5-(4,6-dichlorotriazinyl) aminofluorescein (5-DTAF) in 0.1 M sodium
bicarbonate (pH 9.0), washed with 0.1% Triton X-100 in PBS 3 	 15
min, stained for 30 min with 5 M Bodipy 558/568 C12 (Life
Technologies) in PBS, washed with PBS for 3 	 5 min, and stored in
PBS at 4°C prior to imaging. Samples were imaged using a Leica SP5
AOBS scanning confocal microscope and a 	20 0.7 NA multi-
immersion objective with water as the immersion liquid (5-DTAF:
excitation 488 nm, emission between 496–553 nm; BODIPY: exci-
tation 561 nm, emission between 572 and 649 nm). Images were
collected in resonant scanning mode with bidirectional scanning of
16,000 Hz, with a line average of 8. Typical z-stacks were 100–130
m in thickness with 1.26 m/z-step. Total volume of DTAF positive
pixels (m3) was collected for analysis with Imaris BitPlane software.
Gene expression analysis. Total RNA was extracted using a Ribo-
Pure Kit (Ambion, Austin, TX) per the manufacturer’s protocol. RNA
concentration was measured using a NanoDrop ND-1000 Spectropho-
tometer (NanoDrop Technologies, Wilmington, DE). One microgram
of total RNA was reverse transcribed into cDNA using the Super-
Script III reverse transcriptase (Invitrogen), followed by RNase H
treatment according to the manufacturer’s instructions. The quantita-
tive real-time PCR assays utilized gene-specific “inventoried” Taq-
Man primers and FAM-MGB labeled probes (TaqMan Gene Expres-
sion Assays; Applied Biosystems, Foster City, CA) and were analyzed
in triplicate for each sample using an ABI 7900HT instrument.
Reactions were carried out in a 384-well format containing the
following in each well: cDNA corresponding to 20 ng of original total
RNA, 1	 specific primer probe mix, and 1	 Master Mix (ABI
Taqman Gene Expression Master Mix); cDNA was air-dried in each
well prior to quantitative PCR reagents being added to facilitate an 8
l/well assay. Cycle conditions were 50°C for 2 min, 95°C for 10
min, and then 40 cycles of 95°C for 15 s/60°C for 1 min. Amplifi-
cation cycle threshold (CT) number of housekeeping mRNA [hypo-
xanthine phosphoribosyltransferase 1; shown to be a reliable house-
keeping gene in adipose tissue (19)] for each sample was determined
to correct for template loading differences across all target genes (
CT 
target gene CT  reference gene CT), and expression values were
determined relative to treatment control transcript levels using a
previously described mathematical formula (36).
Plasma cytokine/chemokine panel. Plasma cytokine and chemokine
analysis was performed using Meso Scale Discovery (MSD, Rock-
ville, MD) technology multiplex electrochemiluminescence according
to the manufacturer’s directions. Briefly, 25 mg of EDTA venous
plasma (collected during surgery) was thawed and assayed for proin-
flammatory cytokines (kit no. K15007C) or chemokines (kit no.
K15001C) using MSD’s Sector Imager 2400 machine.
Statistical analysis. For between-group comparisons for Col6KO
studies and human studies comparing healthy and MetS or healthy and
T2DM subjects, Student’s t-test was used with P  0.05, which was
considered significant. Unless otherwise noted, sample sizes for hu-
man studies were n  12 (healthy) or n  10 (MetS or T2DM); some
variables differed in sample sizes due to technical issues (e.g., poor
quality tissue fixation/staining or RNA) or a lack of adequate sample.
Multivariate statistical modeling using partial least squares-discrimi-
nant analysis (PLS-DA) to compare healthy and MetS subjects was
conducted using scaled and centered standard deviation-normalized
data (SIMCA P, version 13.0; Umetrics, San Jose, CA).
RESULTS
Validation of novel tensile strength and three-dimensional
imaging measurements using WAT from collagen 6a1 knockout
mice. Collagen VI is abundant in adipose tissue, and since
knockout of Col6a1 significantly reduces fibrosis in obese mice
(21), we reasoned that this model would display reduced tensile
strength compared with WT mice and thus serve as a good
positive control for the method development. Using a modified
tissue puller (Fig. 1), the force parameters were found to be
significantly different in the RP WAT of collagen 6a1 knockout
(Col6KO) mice compared with WT mice; Col6KO mice had
significantly lower RP WAT tensile strength (calculated with
either an assumed rectangular or oval cross sectional area)
compared with WT mice (Table 1). The peak force/WAT pad
mass and peak force/WAT pad volume were also calculated.
Fig. 1. Apparatus for white adipose tissue (WAT) tensile strength measurement
(A) and force/displacement curve example from murine retroperitoneal (RP)
WAT (B). A DMT560 tissue puller with custom clamps used for measuring
peak force of fresh murine RP WAT was used to measure slope, peak force,
and tensile strength (see METHODS). Following peak force, the tissue begins to
rupture, thus resulting in variable reductions in force/displacement, as
illustrated.
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These studies established that measurement of WAT tensile
strength on a tissue puller is feasible and could discriminate
between groups with differing collagen content and structure.
Col6KO collagen volume by confocal microscopy. Tradi-
tional histological approaches to visualizing and measuring
collagen are limited by lack of three-dimensional information
and may lead to stereoscopic bias and semiquantitative results.
We wished to develop a method to measure ECM volume
stereoscopically and quantitatively, and similarly to tensile
strength measurements, Col6KO mice were used to validate
this approach. The protein-binding chemical 5-DTAF was used
as an alternative to anti-collagen antibodies (6, 20, 24, 60)
since comprehensive preliminary studies with a variety of
methods and antibodies indicated poor depth of antibody pen-
etration into WAT. The murine RP WAT used for validation
and analysis had the anatomic feature of a collagen sheath
surrounding the fat pad (Fig. 2A); DTAF quantitation was
performed without this layer included (see Fig. 2 legend).
Using the 5-DTAF staining approach, we were able to quantify
significantly lower collagen content in RP WAT from Col6KO
mice compared with WT mice (Fig. 2B). As a validation using
more traditional methods, imaging analysis of Sirius red his-
tology on paraffin-embedded WAT sections also showed a
significantly lower collagen content in sc WAT from Col6KO
mice compared with WT (Fig. 2C), and although not quanti-
fied, the adipocytes in the KO mice were clearly much larger in
size. These data indicate that confocal microscopy of 5-DTAF
staining in a three-dimensional volume in WAT is feasible and
can differentiate between models of varied collagen content.
However, we were unable to use this method to differentiate
Table 1. Biophysical tensile strength parameters in RP WAT







Tensile strength (peak force/rectangular
cross-sectional area), mN/mm2 10.43  2.49 5.12  0.60 0.0442
Oval tensile strength (peak force/oval
cross-sectional area), mN/mm2 13.28  3.17 6.52  0.76 0.0442
Fold tensile strength vs. WT 1.00  0.189 0.50  0.05 0.0274
Force/WAT pad mass, mN/g 479  102 253  16 NS
Force/rectangular volume, mN/mm3 0.74  0.17 0.34  0.03 0.0232
Force/column volume, mN/mm3 0.95  0.22 0.43  0.04 0.0232
Values are means  SE. RP, retroperitoneal; WAT, white adipose tissue;
WT, wild type; Col6KO, collagen 6a1 knockout; NS, not significant.
Fig. 2. Mouse RP WAT collagen (extracellular matrix) content as measured by 5-(4,6-dichlorotriazinyl) aminofluorescein (5-DTAF) staining/confocal
microscopy (A and B) and Sirius red histological staining (C): collagen is stained green (5-DTAF) and adipocytes are red (Bodipy 558/568 C12). In A, the starting
image illustrating the collagen sheath typical of murine RP WAT surrounding the depot is depicted; to reduce variance and provide a more uniform method that
could be applied to human WAT biopsies lacking a sheath, this layer was not included in the calculations shown in B. Values are presented as means  SE
comparing wild-type (WT) and collagen 6a1 knockout (Col6a) knockout mice. *Statistically significant at P  0.05 by Student’s t-test. Bar, 100 m.
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collagen bundle/fibril sizes, one of our goals, because the
resolution was not adequate.
Clinical status markers, plasma cytokines, and WAT ECM
factors in healthy obese women or those with MetS. Subject
characteristics are shown in Table 2 and have been described
previously in terms of insulin resistance and elevated serum
triglycerides in the MetS group (25). The obese MetS group
had significantly greater serum alanine aminotransferase, a
marker that increases with liver dysfunction and steatosis, and
serum total protein, a measurement that increases with deteri-
oration of liver and kidney function. The average categorical
degree of steatosis was increased in the obese MetS group.
With respect to adipocyte size, there was a trend for more
hypertrophic adipocytes in the omental WAT from the obese
MetS group compared with the obese healthy group, but this
did not reach statistical significance, and there were no distinct
differences in SC WAT (Fig. 3).
Since metabolic dysfunction can involve inflammation and
immune cells such as macrophages are important participants
in ECM remodeling, a suite of inflammation-related blood
analytes and WAT gene transcript levels were measured. These
included macrophage markers, proinflammatory cytokines, and
anti-inflammatory cytokines. As expected, the MetS obese
group had significantly increased plasma IFN and TNF
compared with the healthy obese group (Table 3). None of the
other measured plasma cytokines or chemokines differed sig-
nificantly between the healthy obese and MetS obese groups,
although most concentrations were increased in absolute terms.
MetS was also characterized by increased transcript abun-
dances for the WAT inflammation and pan-macrophage infiltra-
tion marker CD68 (Table 4). In omental WAT, upward trends in
other inflammation-related transcripts were not statistically signif-
icant, which was probably due to high person-to-person variabil-
ity and a limited sample size. In sc WAT, mRNA abundances
for CD68 and integrin X (ITGAX; CD11c) were increased in
the MetS group, but these trends did not reach statistical
significance (Table 4).
We next sought to further refine the MetS metabolic pheno-
type from that of healthy weight-matched obese subjects
through determinations of omental and sc WAT ECM param-
eters such as tensile strength, three-dimensional measurements
of collagen content, and zymography. There was a 19%
reduction in omental WAT tensile strength in MetS subjects
that was not statistically significant, and there were no
significant differences between MetS and healthy controls
with respect to omental or sc MMP activities and collagen
content as measured by three-dimensional confocal micros-
copy (Tables 5 and 6). Interestingly, there were distinct depot-
related differences when omental and sc WAT ECM properties
were compared directly regardless of disease status, with
omental WAT displaying significantly greater tensile strength
(Table 7). In healthy individuals, but not in MetS subjects,
pro-MMP-9 activity was higher and overall MMP activity
derived from an OmniMMP assay lower in sc WAT compared
with omental. This suggests that MetS somehow attenuates
WAT depot differences in these parameters.
Development of a phenotype “signature” of MetS using
multivariate statistical modeling. There are limitations in the
sole use of iterative pairwise comparisons of individual out-
come variables since variation in some factors that do not
achieve statistical significance may nevertheless contribute to
the phenotypic discrimination of groups. To account for these
shortcomings and to understand which phenotypic variables
best discriminate between healthy and unhealthy obesity, we
leveraged PLS-DA multivariate statistical modeling of all clin-
ical, ECM, and inflammation parameters in healthy and MetS
subjects in the study. Typically, parameters with a PLS-DA
variable influence on projection (VIP) score 1 explain most
of the variance between groups, whereas those with 1  VIP 
0.5 may also contribute, but with less confidence. Using a VIP
cutoff of 0.8 and greater, features were selected from an initial
PLS-DA model to derive a new model that best discriminated
the subject cohorts (Fig. 4A). The subject scores plot derived
from these variables (Fig. 4A) illustrates that variance in this
subset of factors contributed to distinct separation of the
individual subjects into their respective groups, providing a
phenotype “signature” of MetS. A depiction of the relative
contributions of specific variables to subject group separation
is shown as the factor loadings plot in Fig. 4B.
As anticipated, features such as insulin sensitivity indices
(e.g., quantitative insulin sensitivity check index, HOMA-IR)
and certain plasma and adipose inflammation markers [e.g.,
plasma cytokines and chemokines and WAT mRNAs for the
pan-macrophage cell surface marker CD68 as well as the M1
marker ITGAX (CD11c)] strongly contributed to the model
differentiating MetS from healthy obesity (Fig. 4B). The ab-
solute values of these parameters also tracked MetS status in an
expected direction since MetS is associated with insulin resis-
tance and inflammation (see associated tables). Transcript for
ARG2 (arginase 2; a marker associated with alternatively
activated M2 macrophages) was included in the model, and its
expression was reduced in MetS sc WAT, consistent with a
Table 2. Clinical characteristics of obese healthy women
and those with MetS characterized for WAT ECM,
metabolic, and inflammatory phenotypes*
Healthy Obese n  12 MetS Obese n  10 P Value
Age, yr 39  3.6 41  3.4 NS
BMI 40.5  1.0 43.6  2.3 NS
Plasma glucose, mg/dl 88  1 101  3 0.0006
Serum insulin, U/ml 14  1 53  17 0.016
QUICKI 0.327  0.004 0.277  0.006 <0.0001
Triglycerides, mg/dl 85  7 132  15 0.009
Total cholesterol, mg/dl 191  13 184  11 NS
LDL cholesterol, mg/dl 125  11 113  9 NS
HDL cholesterol, mg/dl 49  2.9 44  4.4 NS
Systolic BP, mmHg 123  2.3 130  4.3 NS
Diastolic BP, mmHg 73  1.3 77  1.8 NS
Serum ALT, IU/l 24  3 45  9 0.025
Serum AST, IU/l 21  2 41  11 NS
Steatosis** 0.5  0.2 1.2  0.3 0.048
Serum protein, g/dl 7.1  0.1 7.6  0.2 0.003
hsCRP, mg/l 0.8  0.2 0.8  0.2 NS
Data are presented as means  SE. MetS, metabolic syndrome; ECM,
extracellular matrix; BMI, body mass index; QUICKI, quantitative insulin
sensitivity check index, calculated as 1/[log (insulin U/ml)  log (glucose
mg/dl)]; BP, blood pressure; ALT, alanine aminotransferase; AST, aspartate
aminotransferase; hsCRP, high-sensitivity C-reactive protein. *Clinical values
are in the overnight-fasted state taken 1–2 wk before bariatric surgery.
**Blinded clinical pathology score derived from histology of surgical liver
biopsy (scale 0–3: 0  none, 5% steatosis; 1  mild, 5–33% steatosis; 2 
moderate, 34–66% steatosis; 3  severe, 66% steatosis); n  11 for healthy
steatosis score. Comparisons with P  0.05 by Student’s t-test are considered
significantly different. Significant values are in boldface.
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proinflammatory state. The model factor serum ferritin has
been reported to be associated with many insulin-resistant
states, including T2DM, metabolic syndrome, gestational dia-
betes, and polycystic ovarian syndrome as an acute phase
protein (40), and was increased in MetS. Subjects’ clinical
pathology liver steatosis scores contributed to the model, and
the value of this factor was increased in MetS.
Twenty ECM-relevant parameters also contributed to the
PLS-DA model (asterisks in Fig. 4B factor loadings plot),
indicating important MetS-associated changes in both omental
and sc ECM. For instance, mRNA abundance of CTSS (ca-
thepsin S; a member of the peptidase C1 family) in both
omental and sc WAT was part of the MetS phenotype signa-
ture, and this factor was higher in MetS compared with healthy
obese. MMP-9, an MMP expressed abundantly by immune
cells, also contributed to the model distinguishing MetS and
healthy obese subjects. Notably, there were lower activities of
both pro-MMP-9 and pro-MMP-9 dimer in MetS sc WAT, as
measured by gelatin zymography despite higher MMP-9
mRNA abundance. mRNA expression levels for sc WAT
MMP7 and SERPINE (PAI-1) also contributed to the MetS
phenotype model and displayed higher expression in MetS.
Results from the OmniMMP assay that measures nonspecific
MMP activity helped drive separation of the groups, and it was
interesting that sc and omental WAT displayed contrasting
directionality in the MetS subjects relative to healthy obese
women (Fig. 4B). With respect to collagen, despite no differ-
ences in gross collagen content by DTAF staining or Sirius red
histology (Tables 5 and 6), mRNA abundances of a variety of
collagens in both sc and omental WAT were important con-
tributors to the model distinguishing healthy and MetS subjects
(Fig. 4B). Generally speaking, WAT collagen mRNA expres-
sion levels were reduced in MetS and contributed to the model
(e.g., COL3A1, COL5A2, and COL6A3). Interestingly, omental
WAT tensile strength was also included in the model.
There were several clinical measurements of micronutrient
status whose variances contributed to the MetS phenotype
separation. These included vitamins B1 (thiamine) and B12,
serum zinc, Na, and Cl, although all mean values fell within
normal reference ranges.
Development of an ECM, metabolic, and inflammation phe-
notype profile of T2DM using multivariate statistical modeling.
Our primary focus was to compare healthy and MetS subjects
free of medications that might impact ECM biology. However,
we also took advantage of the opportunity to examine ECM
and other parameters in a cohort of T2DM patients undergoing
bariatric surgery in a secondary analysis of potential diabetes-
associated changes in WAT. The clinical characteristics of this
group compared with the healthy subjects, as well as a com-
parison of plasma cytokines, are provided in Tables 8 and 9,
respectively. In addition to the expected perturbations in insu-
lin and glucose homeostasis, liver steatosis score was increased
Fig. 3. Healthy and metabolic syndrome (MetS) obese human adipocyte size distribution analysis. Adipocyte area was measured from Sirius red-stained paraffin
sections of omental WAT (A) and subcutaneous (sc) WAT surgical biopsies (B). Bars indicate %total cells within the specified cell area range, shown as means 
SE. There were no statistically significant differences between healthy and MetS obese within the same size category, as determined by 1-way ANOVA followed
by Tukey’s post hoc test. Line in histology images indicates 100 m at 	20 magnification.
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in T2DM subjects, and plasma cytokines were generally in-
creased (albeit with high variability and only statistically sig-
nificant for IL-10 and IP-10). WAT inflammation markers are
presented in Table 10, and as for MetS subjects, T2DM women
had increased mRNA expression of CD68 in omental but not sc
WAT. Notably, ARG2, an M2 macrophage marker, was sig-
nificantly reduced in sc but not omental WAT in T2DM.
Differences in omental and sc WAT ECM parameters between
healthy and T2DM subjects are provided in Tables 11 and 12,
respectively. As with MetS subjects, a wide variety of ECM-
related transcripts in both sc and omental WAT were altered
(e.g., collagen transcripts were generally reduced, and MMPs
and inflammation/macrophage markers were generally in-
creased), and there was a 24% reduction in omental WAT
tensile strength reminiscent of that observed in MetS subjects.
Many of these ECM factors contributed to the PLS-DA model
that discriminated T2DM from healthy subjects (Fig. 5, A and B).
Omental tensile strength was included in the model, as were
other expected clinical markers of metabolic dysfunction and
inflammation, including insulin resistance indices and Hb A1c,
serum triglycerides, and liver steatosis score.
DISCUSSION
That central obesity, as a part of the diagnostic criteria for
MetS, is often accompanied by inflammation and insulin re-
sistance is well established (15), but the underlying basis is the
subject of debate. Obesity does not always manifest with
metabolic disease, suggesting that there are innate differences
among individuals with respect to the health consequences of
WAT expansion (58). One possibility is that in susceptible
individuals, adipocyte hypertrophy and caloric excess drive
oxidative stress, and after a “tipping point” of metabolic and
inflammatory events has been reached, disease ensues. It has
been proposed that focal tissue hypoxia, due to a mismatch of
WAT hypertrophy and vasculogenesis, contributes and elicits a
proinflammatory response (48). Fibrosis is also thought to play
a role in adipose and hepatic inflammation, and it has been
proposed that excess fibrosis in WAT hinders adipocyte hy-
pertrophy and WAT remodeling during periods of overnutri-
tion (as reviewed in Refs. 8, 14, and 48). On the other hand, in
healthy obesity, we hypothesize that orderly expansion of
WAT with concurrent well-regulated remodeling of vascula-
ture, collagens, and other ECM components takes place as an
adaptational response to store excess calories. An analogy is
wound healing, in which injury-disrupted ECM (e.g., via in-
tegrin and matrix component cell surface signaling) elicits an
orchestrated response that involves M2-like macrophage infil-
tration and ECM remodeling for proper tissue repair (48).
Might unhealthy obesity be characterized by disordered WAT
ECM and compromised WAT architecture? Current tools to
quantitate the WAT ECM are not optimal since they cannot
quantify collagen bundle/fibril sizes, detailed architectural fea-
tures, or functional outcomes such as tissue integrity that
would be expected to track disordered ECM. Thus, novel
methods to quantify WAT collagen ECM volume in 3D and to
measure biophysical properties of WAT samples were devel-
oped, combining these approaches with traditional ECM and
inflammation measurements to determine phenotype shifts in
the WAT of metabolically compromised obesity. To our
knowledge, this is the first report using these approaches. Our
results in a cohort of matched eqally obese women support the
concept that differences in adipose ECM and related variables
Table 3. Plasma concentrations of cytokines and chemokines
in healthy obese women compared with those with MetS*
Healthy Obese n  11 MetS Obese n  9 P Value
GM-CSF 0.083  0.047 0.038  0.032 0.47
IFN- 0.59  0.15 1.60  0.42 0.02
IL-1 0.40  0.056 0.63  0.18 0.21
IL-2 0.067  0.027 0.32  0.24 0.26
IL-6 3.01  0.46 3.71  0.49 0.31
IL-8 8.0  0.8 9.8  1.0 0.16
IL-10 1.62  0.17 2.27  0.35 0.09
IL-12p70 0.15  0.043 0.59  0.29 0.11
IP-10 215  32 263  60 0.47
TNF 2.93  0.31 4.83  0.43 0.002
Eotaxin 618  79 607  95 0.93
Eotaxin-3 3.9  0.82 5.0  1.1 0.453
MCP-1 272.2  26.4 315.2  41.9 0.38
MCP-4 1,203.6  159.4 1,316.2  201.0 0.66
MDC 4,330  563 4,380  684 0.95
MIP-1 133.6  11.1 138.2  25.2 0.86
TARC 702  202 510  147 0.47
Values are presented as means  SE; units for all cytokines and chemokines
are in pg/ml. GM-CSF, granulocyte macrophage-colony stimulating factor;
MCP-1, monocyte chemoattractant protein-1; MDC, macrophage-derived
chemokine; MIP-1, macrophage inflammatory protein-1; TARC, thymus
and activation-regulated chemokine/CCL17. *Samples were collected at the
time of bariatric surgery. Comparisons with P  0.05 by Student’s t-test are
considered significantly different, and there was a trend (P  0.1) for altered
IL-10 concentrations between groups (values in boldface).
Table 4. WAT inflammation-associated gene expression in
healthy obese women compared with those with MetS*
Healthy Obese MetS Obese P Value
Omental WAT
CD68 100.0  13.7 197.0  44.6* 0.03
ITGAX 100.0  20.2 179.5  50.4 0.13
ITGAD 100.0  30.2 166.2  50.5 0.26
TNF 100.0  14.5 103.1  37.0 0.93
IL6 100.0  88.7 185.5  106.7 0.54
IL1B 100.0  31.0 125.9  30.8 0.57
CCL2 100.0  37.5 71.3  15.8 0.52
NOS2 100.0  21.3 103.5  37.6 0.93
THBS1 100.0  21.7 125.3  26.9 0.47
TGFB1 100.0  19.2 161.1  31.5 0.10
ARG2 100.0  29.2 98.3  23.6 0.97
sc WAT
CD68 100.0  15.9 191.1  46.7 0.06
ITGAX 100.0  19.2 354.6  150.8 0.08
ITGAD 100.0  29.7 120.2  45.8 0.70
TNF 100.0  21.6 130.2  37.3 0.47
IL6 100.0  90.5 17.7  10.5 0.44
IL1B 100.0  23.1 72.4  38.0 0.53
CCL2 100.0  22.4 64.0  33.5 0.37
NOS2 100.0  15.3 85.5  25.9 0.62
THBS1 100.0  21.7 69.0  16.2 0.30
TGFB1 100.0  13.7 102.6  18.3 0.91
ARG2 100.0  16.7 64.5  14.8 0.15
Values are presented as means  SE. ITGAX, integrin X; ITGAD, integrin
D; CCL2, C-C motif ligand 2; NOS2, nitric oxide synthase; THBS1, throm-
bospondin-1; TGFB1, transforming growth factor-B1; ARG2, arginase 2; sc,
subcutaneous. *mRNA abundances measured in a subset of subjects with
available samples, expressed as percent of healthy obese group mean (for
omental WAT: n  11 and 9 in healthy and MetS groups, respectively; for sc
WAT: n  9 and 7 for healthy and MetS, respectively, for mRNA). Values that
differ significantly (P  0.05) or display trends (P  0.1) by Student’s t-test
are indicated in boldface.
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readily differentiate healthy and unhealthy obesity, although
cause/effect remains to be established.
The results indicate that tensile strength measurement is a
promising tool for examining adipose tissue integrity and ECM
structure/function, since in Col6KO mice there was a signifi-
cant decrease in tensile strength compared with WT mice, and
omental tensile strength was a contributing feature in PLS-DA
statistical models distinguishing healthy vs. metabolically
compromised obesity. However, this technology requires fur-
ther refinement for human applications, since we observed high
subject-to-subject variability. A major difference between the
human and mouse studies was the ability to finely dissect the
entire WAT pad in the mouse vs. more variable collection and
preparation techniques for the large biopsy samples collected at
the time of surgery in humans. This would have made it more
difficult to detect MetS- and T2DM-associated differences in
tensile strength in the human comparisons for which orienta-
tion of the tissue, exact site of collection, etc., can be difficult
to control. Nevertheless, we were able to clearly demonstrate
significant depot effects, with human omental WAT displaying
much higher tensile strength compared with sc WAT. The
reason for this depot specificity is not entirely clear but likely
involves architectural differences and roles associated with the
different depots. Subcutaneous WAT, for instance, may require
more malleability to accommodate energy storage and adi-
pocyte hypertophy compared with the omental depot. The sc
WAT also has important roles for insulation and protection of
Table 5. Omental WAT ECM parameters in healthy obese
women and those with MetS
Healthy Obese MetS Obese P Value
Tensile strength, mN/mm2 34.7  4.2 28.3  4.4 0.31
Sirius red (collagen) 5,180  1,880 5,404  1,909 0.93
DTAF (collagen/ECM) 0.077  0.010 0.073  0.011 0.82
Zymography (AU)
Pro-MMP-9 0.59  0.13 0.70  0.14 0.59
Pro-MMP-2 0.99  0.40 0.70  0.14 0.52
OmniMMP* 667  54 514  113 0.21
Gene expression**
COL1A2 100.0  12.3 88.0  12.2 0.50
COL3A1 100.0  13.1 80.0  13.3 0.29
COL5A2 100.0  10.7 79.7  13.9 0.25
COL6A3 100.0  12.2 64.0  9.6 0.04
COL8A1 100.0  15.8 121.5  37.9 0.58
ELN 100.0  9.6 115.3  22.2 0.51
TNC 100.0  25.3 98.8  21.8 0.97
BGN 100.0  13.8 93.5  16.8 0.77
DCN 100.0  14.9 90.5  9.7 0.62
LUM 100.0  13.5 113.4  19.8 0.57
FBN1 100.0  16.6 99.7  21.6 0.99
MFAP5 100.0  21.1 113.4  35.4 0.74
MMP-2 100.0  12.4 90.2  18.4 0.65
MMP-7 100.0  59.9 112.6  29.2 0.86
MMP-9 100.0  36.5 100.2  25.4 0.99
MMP-14 100.0  11.2 92.9  15.6 0.71
CTSK 100.0  14.6 102.3  12.3 0.91
CTSL1 100.0  14.5 104.9  19.3 0.84
CTSS 100.0  19.2 155.7  43.8 0.23
SERPINE1 100.0  35.1 368.1  113.6 0.02
PLAUR 100.0  18.8 155.8  26.6 0.09
Data are presented as means  SE; n  10 and n  9 for healthy Sirius red
and pro-matrix metalloproteinase-2 (MMP-2), respectively, and n  9, 6, and
8 for MetS tensile strength, 5-(4,6-dichlorotriazinyl) aminofluorescein (5-
DTAF), and pro-MMP-2, respectively. AU, arbitrary units; CTSK, cathepsin
K; CTSL1, cathepsin L1; CTSS, cathepsin S; *OmniMMP units are emission at
405 nm minus blank. **mRNA abundances measured in a subset of subjects
with available samples, expressed as percent of healthy obese group mean
(n  11 and 9 in healthy and MetS groups, respectively, for mRNA).
Comparisons with P  0.05 by Student’s t-test are considered significantly
different, and there was a trend for PLAUR (in boldface).
Table 6. Subcuteanous WAT ECM parameters in healthy
obese women compared with those with MetS
Healthy Obese MetS Obese P Value
Tensile strength, mN/mm2 13.7  2.5 10.4  2.3 0.36
Sirius red (collagen) 1,688  386 1,326  498 0.57
DTAF (collagen/ECM) 0.095  0.010 0.092  0.017 0.88
Zymography (AU)
Pro-MMP-9 1.20  0.23 0.88  0.13 0.30
Pro-MMP-2 0.68  0.22 0.89  0.18 0.49
OmniMMP* 492  52 629  135 0.31
Gene Expression**
COL1A2 100.0  17.2 81.9  18.7 0.49
COL3A1 100.0  12.7 78.3  10.9 0.23
COL5A2 100.0  20.4 72.2  8.8 0.28
COL6A3 100.0  19.9 73.7  12.2 0.31
COL8A1 100.0  16.4 77.2  25.9 0.45
ELN 100.0  22.2 116.5  38.7 0.70
TNC 100.0  25.7 94.7  10.7 0.87
BGN 100.0  6.2 108.0  27.9 0.76
DCN 100.0  17.8 87.1  21.1 0.65
LUM 100.0  17.7 107.8  36.4 0.84
FBN1 100.0  17.3 92.2  24.0 0.79
MFAP5 100.0  24.4 109.2  25.3 0.80
MMP2 100.0  24.5 103.9  25.3 0.91
MMP7 100.0  23.3 328.2  139.3 0.09
MMP9 100.0  17.5 250.0  114.9 0.16
MMP14 100.0  19.0 107.2  34.5 0.85
CTSK 100.0  11.8 87.8  23.3 0.62
CTSL1 100.0  8.7 92.3  16.5 0.67
CTSS 100.0  9.3 173.8  41.1 0.07
SERPINE1 100.0  35.5 97.4  17.4 0.95
PLAUR 100.0  15.9 121.7  31.0 0.51
Data are presented as means  SE; n  11 and n  9 for healthy tensile
strength and Sirius red, and n  5–9 for MetS tensile strength, Sirius red,
5-DTAF, and MMP measurements. *OmniMMP units are emission at 405 nm
minus blank. **mRNA abundances measured in a subset of subjects with
available samples, expressed as percent of healthy obese group mean (n  9
and 7 for healthy and MetS, respectively, for mRNA). Statistical comparisons
by Student’s t-test; there were potential trends (P  0.1) in MMP-7 and CTSS
(values shown in boldface). One healthy subject had a Sirius red value of
122,296 and was thus excluded as an outlier.
Table 7. Comparison of sc and omental WAT ECM parameters
in healthy obese women compared with those with MetS
Healthy Obese MetS Obese
Tensile strength (omental) 34.7  4.2 28.3  4.4
Tensile strength (sc) 13.7  2.5*** 10.4  2.3**
DTAF (omental) 0.077  0.010 0.073  0.011
DTAF (sc) 0.095  0.010 0.092  0.017
Zymography
Pro-MMP-9 (omental) 0.59  0.13 0.70  0.14
Pro-MMP-9 (sc) 1.20  0.23* 0.88  0.13
Pro-MMP-2 (omental) 0.99  0.40 0.70  0.14
Pro-MMP-2 (sc) 0.68  0.22 0.89  0.18
OmniMMP (omental) 667  54 514  113
OmniMMP (sc) 492  52* 629  135
Values are presented as means  SE. Units: tensile strength (mN/mm2),
5-DTAF (m3), MMP-9, and MMP-2 (arbitrary densitometry units); Omn-
iMMP (emission at 405 nm; blank value). Significantly different from omental
(*P  0.05, **P  0.01, and ***P  0.001). Significant values are in
boldface.
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the body, and this might also help explain, from a teleologic
standpoint, differences in biophysical properties of this depot
compared with visceral adipose tissue.
In addition to measurement of gross collagen content, we
had hoped to determine subtleties of ECM architecture such as
fibril/bundle size differences in healthy and MetS women.
However, the three-dimensional collagen imaging technology
that was developed for these purposes was not of high enough
resolution. Nevertheless, this quantitative method correlated
well with traditional histological measurements of total colla-
gen and allowed measurements to to be made in a defined
volume of WAT. Future studies should consider application of
electron microscopy or other imaging approaches to achieve
the goal of fibril subtype quantitation and to quantify the extent
of ordered vs. disordered ECM structures. This could be
important because we suspect that gross collagen content may
not change when healthy and diseased WAT are compared, but
there could be irregular collagen architecture in MetS or other
metabolic disorders (analogous to tissue injury or poor wound
healing) that contribute to inflammation and disease pheno-
types. Furthermore, DTAF marks protein and not collagen
specifically, so although it is useful for general quantitation of
ECM (composed mostly of collagens), its signal may not
always correlate with more refined measurements of collagen
subtypes (as seen herein for collagen transcripts that differed in
MetS and T2DM). Thus, new collagen-specific methods to
quantitate WAT ECM should be pursued.
Traditional pairwise comparisons to determine differences
between groups do not take into consideration the networked
covariate nature of many systems. To identify new factors that
mark the MetS condition, and to determine whether WAT
ECM-relevant factors contribute to the MetS phenotype, we
employed multivariate statistical analysis to identify healthy
and MetS “signatures.” To accomplish this, we selected sub-
jects not being treated with statins and TZDs, which have been
shown to alter ECM dynamics in other tissues such as the liver,
Fig. 4. Results from partial least squares-discriminant analysis (PLS-DA) modeling of clinical and WAT phenotype variables to identify features that differentiate
healthy obese and MetS obese women. A: subjects scores plot illustrating individuals from the healthy (green) and MetS (pink) cohorts, showing separation of
groups along latent variable 1 dimension (x-axis). B: scores separation along the x-axis dimension in A was explained primarily by variance in features depicted
in the loadings plot. HOMA-IR, homeostasis model assessment of insulin resistance; BUN, blood urea nitrogren; ALT, alanine aminotransferase; CTSS,
cathepsin S; ITGAX, integrin X; MMP-7 and -9, matrix metalloproteinase-7 and -9, respectively; WBC, white blood cell; AST, aspartate aminotransferase; BP,
blood pressure; ITGAD, integrin D; BGN, biglycan; THBS1, thrombospondin-1; QUICKI, quantitative insulin sensitivity check index; ARG2, arginase 2; ECM,
extracellular matrix.
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the immune system, and the heart (9, 17, 26, 39). These
analyses confirmed the central hypothesis that factors associ-
ated with WAT architectural and biophysical properties, e.g.,
collagens, MMPs, and tensile strength, are altered in the MetS
state. For instance, changes in production of collagen molecule
transcripts, proteolytic enzyme transcripts, proteolytic activity,
and overall omental WAT tensile strength were features that
discriminated healthy vs. MetS obese subjects in the PLS-DA
model. Variance in omental WAT tensile strength in the MetS
obese group that contributed to the PLS-DA model may indi-
cate a greater degree of disordered ECM compared with the
healthy obese, but this postulate will require experimental
validation. We found that transcript levels of COL3A1,
COL5A2, and COL6A3 were decreased in both the omental and
sc WAT of the MetS obese group in the PLS model. These
results were somewhat unexpected, as it has been shown
previously that these collagen genes are increased with obesity
(10). Specifically, it has been found in both humans and mouse
models that increased levels of collagen VI are associated with
decreased insulin sensitivity in obesity (21, 38). Similarly,
collagen V gene expression negatively correlated with insulin
sensitivity in lean and obese humans (44). It is possible that the
decreased expression of the collagen genes in the obese MetS
group partially explains the subtle but decreased omental WAT
tensile strength in this group.
It has been shown previously that circulating MMP-9 levels
are increased in obesity and correlate with insulin resistance
(55). Increased MMP-9 transcript has also been found to
correlate with increased HOMA-IR in sc WAT and omental
WAT of obese subjects (54). However, our study showed
contradictory results with increased MMP-9 gene expression in
sc WAT but decreased pro-MMP-9 activity by zymography,
with no differences in omental WAT in MetS. Circulating
MMP-7 was reported to be decreased in obesity and to increase
after bariatric surgery (41), but in the current study we showed
that MetS subjects had higher sc WAT MMP-7 gene expres-
sion than healthy obese subjects. Overall, MMP activity as
measured by the OmniMMP assay was increased in sc WAT
and decreased in omental WAT of MetS subjects. Expression
of CTSS, a cysteine protease whose expression in adipose is
strongly correlated with BMI and decreases with weight loss
Table 8. Clinical characteristics of obese healthy
and T2DM women
Healthy Obese n  12 T2DM Obese n  10 P Value
Age, yr 39  3.6 46  3.3 0.22
BMI 40.5  1.0 40.8  1.9 0.88
Plasma glucose, mg/dl 88  1.2 139  12.2 0.0001
Serum insulin, U/ml 14  1.1 35  5.2 0.0002
QUICKI 0.327  0.004 0.278  0.007 <0.0001
Triglycerides, mg/dl 85  7.4 267  81.0 0.018
Total cholesterol mg/dl 191  13 192  15 0.96
LDL cholesterol, mg/dl 125  11 104  12 0.21
HDL cholesterol, mg/dl 49  2.9 46  5.1 0.59
Systolic BP, mmHg 123  2.3 130  3.8 0.10
Diastolic BP, mmHg 73  1.3 77  2.8 0.23
Serum ALT, IU/l 24  3 25  4 0.81
Serum AST, IU/l 21  2 24  2 0.13
Steatosis* 0.5  0.2 1.3  0.2 0.01
Serum protein, g/dl 7.1  0.1 7.2  0.1 0.52
hsCRP, mg/l 0.8  0.2 0.7  0.2 0.72
Data are presented as means  SE. Healthy obese values are from Table 2;
n  10 for T2DM, except n  9 for clinical chemistries. T2DM, type 2
diabetic. Clinical values are in the overnight-fasted state taken 1–2 wk before
bariatric surgery. *Blinded clinical pathology score derived from histology of
surgical liver biopsy (scale 0–3; 0  none, 5% steatosis; 1  mild, 5–33%
steatosis; 2  moderate, 34-66% steatosis; 3  severe, 66% steatosis).
Comparisons with P  0.05 by Student’s t-test are considered significantly
different. QUICKI is calculated as 1/[log (insulin U/ml)  log (glucose
mg/dl)]. Significant values are in boldface.
Table 9. Plasma concentrations of cytokines in obese
healthy and T2DM women*
Healthy Obese T2DM Obese P Value
GM-CSF 0.083  0.047 0.109  0.062 0.74
IFN 0.59  0.15 1.63  0.87 0.23
IL-1 0.40  0.056 0.40  0.090 0.96
IL-2 0.067  0.027 0.150  0.051 0.15
IL-6 3.01  0.46 4.71  1.04 0.14
IL-8 8.0  0.8 10.2  1.4 0.17
IL-10 1.62  0.17 2.35  0.32 0.05
IL-12p70 0.15  0.043 0.25  0.076 0.26
IP-10 215  32 428  93 0.04
TNF 2.93  0.31 7.32  2.92 0.13
Eotaxin 618  79 761  106 0.29
Eotaxin-3 3.9  0.82 3.2  0.54 0.47
MCP-1 272.2  26.4 327.6  33.7 0.21
MCP-4 1,203.6  159.4 1,374.0  300.5 0.61
MDC 4,330  563 5,003  562 0.41
MIP-1 133.6  11.1 137.7  17.7 0.84
TARC 702  202 882  277 0.60
Values are presented as means  SE. Plasma concentration units are pg/ml;
n  11 and 10 for healthy and T2DM subjects, respectively. *Samples
collected at the time of bariatric surgery. Comparisons with P  0.05 by
Student’s t-test are considered significantly different and are indicated in
boldface.
Table 10. WAT inflammation-associated gene expression
in obese healthy and T2DM women*
Healthy Obese T2DM Obese P Value
Omental WAT
CD68 100.0  13.7 219.9  47.1 0.02
ITGAX 100.0  20.2 263.9  64.8 0.02
ITGAD 100.0  30.2 126.9  31.4 0.55
TNF 100.0  14.5 232.3  106.9 0.19
IL6 100.0  88.7 62.6  23.0 0.71
IL1B 100.0  31.0 196.7  47.9 0.10
CCL2 100.0  37.5 117.9  35.2 0.74
NOS2 100.0  21.3 146.3  35.3 0.26
THBS1 100.0  21.7 83.8  17.6 0.58
TGFB1 100.0  19.2 177.2  36.5 0.06
ARG2 100.0  29.2 97.2  24.2 0.94
sc WAT
CD68 100.0  15.9 104.4  17.3 0.85
ITGAX 100.0  19.2 122.8  43.3 0.62
ITGAD 100.0  29.7 82.2  34.0 0.71
TNF 100.0  21.6 67.3  15.1 0.24
IL6 100.0  90.5 18.3  5.7 0.41
IL1B 100.0  23.1 71.2  20.9 0.37
CCL2 100.0  22.4 79.2  24.7 0.54
NOS2 100.0  15.3 84.0  22.0 0.55
THBS1 100.0  21.7 41.2  8.3 0.03
TGFB1 100.0  13.7 84.5  16.3 0.47
ARG2 100.0  16.7 57.7  9.2 0.05
Values are presented as means  SE. *mRNA abundances measured in a
subset of subjects with available samples, expressed as percent of healthy
obese group mean (n  11 and 9 for omental; n  9 and 8 for sc WAT in
healthy and T2DM, respectively). Values that differ significantly (P  0.05) or
display potential trends (P  0.1) by Student’s t-test are indicated in boldface.
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(50, 51), was increased in both omental and sc WAT in the
MetS obese group. CTSS expression can be induced in WAT
by TNF and IL-1 (49), both of which were increased in
circulation in the MetS obese group. CTSS has a role in ECM
remodeling through degradation of its substrates elastin,
laminin, fibronectin, and some collagens (50). Thrombospon-
din-1 (encoded by THBS1), an ECM component and compo-
nent of platelet -granules, has been shown to be important in
the WAT accumulation of macrophages in DIO mice, and
thrombospondin deficiency has been found to improve glucose
tolerance and insulin tolerance (27). Coculture of macrophages
and adipocytes increases THBS1 expression in both cell types
(16), and human sc WAT THBS1 expression has been found to
positively correlate with BMI, PAI1 (SERPINE1), MCP1
(CCL2), and CD68 mRNA expression and negatively correlate
with insulin sensitivity (57). In the present study, however,
THBS1 expression was decreased in the MetS group, whereas
both SERPINE1 and CD68 mRNA expression were increased
in the omental WAT alone (SERPINE1) or both WAT depots
(CD68). Thus, although our overall results support the idea that
ECM factors are altered in MetS WAT, there are some dis-
crepancies with prior reports. However, many studies have
compared lean vs. obese individuals, whereas we examined
weight-matched obese, high-BMI women. Furthermore, we
cannot exclude the possibility that nutritional status could
impact these variables; the subjects in the current study were
sampled after 2–3 days of presurgical intestinal preparation
that placed them in a fasting metabolic state.
The phenotypic variables measured herein included macro-
phage markers, since macrophages play an important role in
adipose remodeling during hypertrophy (48). In fact, the
COL63 cleavage product endotrophin has been shown to act
as a macrophage chemoattractant (37). Previously, we have
demonstrated that WAT macrophage infiltration is strongly
correlated with body weight over a large range in nonobese and
moderately obese mice (52, 53), which is indicative of a
normal physiological role for macrophages in the course of
adaptational WAT expansion and remodeling. However,
chronic and extreme obesity can lead to accumulation of
classically activated, proinflammatory CD11c M1 macro-
phages (31, 32). This accumulation switches the balance of
macrophages from tissue remodeling functions to inflamma-
tory functions, leading to insulin resistance (34). In the present
study, examining pairwise comparisons and the PLS-DA
model factors, it was clear that MetS subjects displayed an
expected proinflammatory state systemically and in WAT. For
instance, we found that the pan-macrophage marker CD68 and
a marker of the classically activated M1 macrophage ITGAX
(CD11c) were both increased in omental and sc WAT in MetS
compared with healthy subjects. Plasma IFN was increased in
Table 12. Subcutaneous WAT ECM parameters in obese
healthy and T2DM women
Healthy Obese T2DM Obese P Value
Tensile strength, mN/mm2 13.7  2.5 10.5  2.5 0.38
Sirius red 1,688  386 19,595  10,169 0.80
DTAF (collagen/ECM) 0.095  0.010 0.097  0.008 0.89
Zymography (AU)
Pro-MMP-9 1.20  0.23 1.00  0.24 0.56
Pro-MMP-2 0.68  0.22 0.74  0.16 0.84
OmniMMP* 492  52 874  118 0.005
Gene Expression**
COL1A2 100.0  17.2 95.2  16.6 0.84
COL3A1 100.0  12.7 96.7  15.0 0.87
COL5A2 100.0  20.4 67.2  11.7 0.20
COL6A3 100.0  19.9 61.0  11.8 0.12
COL8A1 100.0  16.4 28.0  8.1 0.002
ELN 100.0  22.2 40.2  8.7 0.03
TNC 100.0  25.7 73.9  16.6 0.42
BGN 100.0  6.2 98.7  15.6 0.93
DCN 100.0  17.8 86.1  16.2 0.57
LUM 100.0  17.7 88.2  19.5 0.66
FBN1 100.0  17.3 44.0  7.7 0.01
MFAP5 100.0  24.4 68.7  16.5 0.32
MMP2 100.0  24.5 90.3  20.6 0.77
MMP7 100.0  23.3 352.2  232.3 0.27
MMP9 100.0  17.5 340.6  118.1 0.05
MMP14 100.0  19.0 53.8  9.4 0.05
CTSK 100.0  11.8 87.4  14.1 0.50
CTSL1 100.0  8.7 65.3  8.5 0.01
CTSS 100.0  9.3 122.2  25.7 0.41
SERPINE1 100.0  35.5 62.5  14.5 0.37
PLAUR 100.0  15.9 84.1  16.5 0.50
Data are presented as means  SE. Healthy obese values are from Table 6;
n  8 and n  9 for T2DM Sirius red and DTAF, respectively. *OmniMMP
units are emission at 405 nm minus blank. **mRNA abundances measured in
a subset of subjects with available sample, expressed as percent of healthy
obese group mean (n  9 and 8 for healthy and T2DM groups, respectively,
for mRNA). Values that differ significantly (P  0.05) or display potential
trends (P  0.1) by Student’s t-test are indicated in boldface.
Table 11. Omental WAT ECM parameters in obese healthy
and T2DM women
Healthy Obese T2DM Obese P Value
Tensile strength, mN/mm2 34.7  4.2 26.5  4.4 0.20
Sirius red 5,180  1,880 9,786  3,698 0.27
DTAF (collagen/ECM) 0.077  0.010 0.076  0.007 0.92
Zymography (AU)
Pro-MMP-9 0.59  0.13 0.93  0.30 0.27
Pro-MMP-2 0.99  0.40 1.53  0.64 0.46
OmniMMP* 667  54 187  85 0.26
Gene Expression**
COL1A2 100.0  12.3 106.6  15.2 0.73
COL3A1 100.0  13.1 102.0  11.5 0.91
COL5A2 100.0  10.7 96.1  14.3 0.82
COL6A3 100.0  12.2 55.3  12.9 0.02
COL8A1 100.0  15.8 80.6  28.1 0.54
ELN 100.0  9.6 128.8  31.4 0.36
TNC 100.0  25.3 292.2  174.8 0.24
BGN 100.0  13.8 109.5  16.7 0.66
DCN 100.0  14.9 90.2  12.4 0.63
LUM 100.0  13.5 118.9  23.4 0.47
FBN1 100.0  16.6 110.4  22.7 0.71
MFAP5 100.0  21.1 178.0  51.6 0.15
MMP2 100.0  12.4 82.1  24.6 0.50
MMP7 100.0  59.9 296.4  146.5 0.20
MMP9 100.0  36.5 181.5  52.3 0.21
MMP14 100.0  11.2 80.7  11.5 0.25
CTSK 100.0  14.6 83.2  16.5 0.45
CTSL1 100.0  14.5 86.0  8.1 0.44
CTSS 100.0  19.2 169.8  28.0 0.05
SERPINE1 100.0  35.1 479.7  206.9 0.06
PLAUR 100.0  18.8 142.9  22.9 0.16
Values are presented as means  SE. Healthy obese values are from Table
5; n  9 for T2DM tensile strength, Sirius red, and 5-DTAF, and n  6 for
pro-MMP-2. OmniMMP units are emission at 405 nm minus blank; **mRNA
abundances measured in a subset of subjects with available samples, expressed
as percent of healthy obese group mean (n  11 and 9 for healthy and T2DM
groups, respectively, for mRNA). Values that differ significantly (P  0.05) or
display potential trends (P  0.1) by Student’s t-test are indicated in boldface.
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the MetS group compared with the healthy obese group. IFN
production by Th1 cells induces TNF and IL-1 production
by macrophages (34). Both of these factors were increased
significantly in the plasma of the MetS group and helped
discriminate groups in the PLS-DA model. Plasma IL-6, an-
other cytokine produced by M1 macrophages, was increased
the MetS obese group. Increased circulatory IL-1 and IL-6
have been found to increase the risk of T2DM together (45)
and have been found to be increased in obese MetS subjects in
conjunction with macrophage infiltration into WAT (5). IL-12,
produced in abundance by M1 macrophages in response to
IFN stimulus (33), was also a feature included in the PLS-DA
model. The mRNA for PAI-1, SERPINE1, produced by both
macrophages and adipocytes and involved in the fibrinolytic
system (43), was found in greater abundance in MetS omental
WAT. These results echo previous studies showing increased
circulating levels of PAI-1 in obese MetS subjects (23) and a
role for PAI-1 in the development of insulin resistance (29) and
may be partially explained by the finding that increased con-
centrations of glucose and free fatty acids increase PAI-1
expression (22, 47). At the same time, gene expression of the
M2 macrophage-associated marker arginase-2 (ARG2) (32, 34)
was decreased in the sc WAT of the MetS obese group.
Overall, inflammatory factors that differ between healthy and
MetS obese fit a model where classically activated M1 mac-
rophages infiltrate the adipose and disturb the balance of
anti-inflammatory, regulatory, and tissue repair macrophages,
contributing to insulin resistance and possibly disordered ECM
in MetS.
Strengths, limitations, and future directions. A strength of
the study was the use of a weight-matched cohort of obese
MetS women for which a healthy comparator group was
identified. This approach abrogates potential confounding is-
sues of weight and adiposity on ECM and other outcomes that
might come into play when lean and obese individuals are
compared, and care was taken to avoid recruitment of subjects
taking medications that might impinge upon the ECM or
adipocyte dynamics. All subjects were in a similar metabolic
state at the time of tissue collection, which is a strength, yet we
cannot exclude that the presurgery fasting condition blunted
Fig. 5. Results from PLS-DA modeling of clinical and WAT phenotype variables to identify features that differentiate healthy obese and T2DM obese women.
A: subjects scores plot illustrating individuals from the healthy (green) and MetS (red) cohorts, showing separation of groups along latent variable 1 dimension
(x-axis). B: scores separation along the x-axis dimension in A was explained primarily by variance in features depicted in the loadings plot. Abbreviations are
defined in tables and Fig. 4 legend.
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potential group differences that would have manifested in the
fed or overnight-fasted situation. Another limitation was that
we did not have information on diet patterns or family history
of MetS, nor did we evaluate dynamic changes in metabolism
or hormones following a meal test or other challenges. Future
studies comparing healthy and unhealthy obesity should focus
on all of these aspects and consider controlled dietary condi-
tions leading up to sample collection. Finally, we acknowledge
that our sample size was limited, and a potential drawback to
multivariate statistical analysis is overfit of data that could lead
to type 1 error with respect to interpretation of a particular
factor’s role in discriminating disease phenotype. Despite these
limitations, our identification of a MetS pathophenotype sig-
nature that includes many ECM factors supports the hypothesis
that adipose architecture and maintenance of orderly WAT
growth are important factors associated with metabolic health.
This point is further supported by the fact that a separate model
of controls vs. type 2 diabetes was also characterized by
significant alterations in the ECM and WAT inflammation,
generally in a manner similar to MetS. It remains to be
determined whether the WAT ECM alterations associated with
MetS and T2DM precede, contribute to, or follow metabolic
perturbations such as insulin resistance and dyslipidemia. Our
study also highlights distinct differences in biophysical prop-
erties and ECM factors comparing human subcutaneous and
omental WAT, which are consistent with new findings on
depot-specific biophysical parameters published during the
preparation of this article (2). Another new study has measured
sc WAT stiffness, which was altered with T2DM status (1).
The novel ECM and inflammatory features identified herein,
and the new methods developed, will enable a closer experi-
mental evaluation of those factors that underlie or contribute to
cardiometabolic disease.
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